Celgene Invests More Into GNS Healthcare and Its Machine Learning Software

WIRE)--GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to massive and diverse data streams to better match drugs and other health interventions to individual patients, today announced that Celgene Corporation has entered into a service and license arrangement for the rights to operate the GNS Healthcare REFS (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform for applications across drug discovery, clinical development, and commercialization and market access. In addition, several GNS causal modeling experts will be brought in-house at Celgene sites to operate the platform. GNS also announced that Celgene has made a second equity investment in GNS. "Companies that embrace data-driven frameworks and culture such as Celgene are gaining a competitive advantage to rapidly generate insights that are simply not possible with any other analytics methodology." This service and license arrangement with embedded GNS employees is a linking of people, process and technology.